- Clinical posters detail results of dose escalation portion of phase 1b/2 trials of ADG126 in combination with...
- Brings deep insight in tumor-specific Treg depletion for anti-CTLA-4 therapies delivered intratumorally to...
SCHEDULE 13G Amendment No.2 ADAGENE INC COMMON STOCK Cusip #005329107 Check the appropriate box to designate the rule...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...
- No dose-limiting toxicities observed when ADG126 combined up to 10 mg/kg with repeat cycles...
SAN DIEGO and SUZHOU, China, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a...
SAN DIEGO and SUZHOU, China, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a...
SAN DIEGO and SUZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a...
- Interim phase 1b/2 data report safety profile of ADG116 across dosing levels, with repeat dosing of more than...
- NEObody technology platform enables dynamic targeting of a distinct epitope of CTLA-4 for enhanced safety and...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C...
- Best-in-class profile demonstrated with repeat dosing across dose levels - - Antitumor activity observed in...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K ...
– Topline data for anti-CTLA-4 antibody, ADG116, shows compelling clinical safety and complete and partial...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.